infection is an increasing threat to critically ill patients in many intensive care units. MRSA bacteraemia is an extreme form of MRSA infection and is a significant cause of morbidity and mortality. This case control study aimed to assess the risk factors and outcomes of MRSA bacteraemia compared to methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia. A total of 21 MRSA bacteraemia and 60 randomly selected MSSA bacteraemia episodes, admitted to the intensive care unit at Royal Perth Hospital between 1997 and 2007, were considered. There was a suggestion that hospitalisation within the preceding six months (P=0.087) and residence in a long-term care facility (P=0.065) were associated with a higher risk of MRSA bacteraemia. MRSA bacteraemia was more often treated with antibiotics to which the pathogen was not susceptible in vitro (38.1% vs 0%, P=0.001), resulting in a longer duration of fever (median 7.0 vs 2.0 days, P=0.009) and bacteraemia (mean 3.2 vs 0.6 days, P=0.005) and a higher incidence of metastatic seeding of infection (52.4% vs 21.7%, P=0.607), a significant proportion of the patients who had MRSA bacteraemia died within five years of hospital discharge (36.4%, hazard ratio 26.0, 95% confidence interval 1.90 to 356.7, P=0.015). Infections contributed to 75% of the deaths after hospital discharge in patients who had an episode of MRSA bacteraemia. MRSA bacteraemia carries a much worse long-term prognosis than MSSA bacteraemia and that could be explained by recurrent MRSA infections and residual confounding.
Methicillin-resistant Staphylococcus aureus (MRSA) infections, either community or healthcareassociated, have increased three-to four-fold in the past 10 years and pose an important threat to patients in many healthcare institutions [1] [2] [3] [4] [5] . Critically ill patients in the intensive care unit (ICU) are particularly at risk for MRSA infections because known risk factors, including advanced age, comorbidities, mechanical ventilation, presense of central venous catheter, prior hospitalisation, receipt of antimicrobial agents prior to admission and the presence of an indwelling urinary catheter are prevalent [4] [5] [6] [7] [8] . MRSA bacteraemia is an extreme form of MRSA infection and is associated with significant morbidity and mortality 7, 8 .
Evidence suggests that MRSA infections may be associated with a worse mortality outcome than methicillin-susceptible Staphylococcus aureus (MSSA) infections [9] [10] [11] [12] . Some strains of communityassociated MRSA can secrete virulence factors, Panton-Valentine-Leukocidin toxin and phenolsoluble modulin peptides, which are toxic to neutrophils, resulting in a higher incidence of necrotising pneumonia and cutaneous abscess 10 . Although recurrent MSSA infections are common, recent evidence suggests that recurrent MRSA infections also appear to be very common in patients colonised with MRSA 13, 14 . As such, long-term outcomes of patients with MRSA infections and bacteraemia may be very different from patients with MSSA infections and bacteraemia, over and above the confounding effect of a delay in initiating appropriate antibiotics 15 .
Anaesthesia and Intensive Care, Vol. 37, No. 3, May 2009 We hypothesised that co-morbidity was an important risk factor for MRSA bacteraemia in critically ill patients, and that hospital and long-term outcomes of MRSA bacteraemia were worse than MSSA bacteraemia after adjusting for patients' comorbidities and other potential confounders.
METHoD
This case control study was registered with the Quality Improvement Unit of Royal Perth Hospital as a clinical audit. Data of all consecutive MRSA bacteraemia episodes (cases) and a random sample of MSSA bacteraemia episodes (controls), admitted to the ICU of Royal Perth Hospital between July 1997 and June 2007, were retrieved from the Microbiology Department Staphylococcus aureus bacteraemia database 3 . An episode of MRSA bacteraemia was defined as the culture of this organism in ≥1 set of blood cultures. If a patient had a positive blood culture for MRSA ≥30 days following the initial blood culture, and the source of the bacteraemia was different from the initial episode, it was considered to be a separate episode. A total of 1125 episodes of Staphylococcus aureus bacteraemia were recorded in the whole hospital during the study period and among these episodes, 204 and 921 were MRSA and MSSA bacteraemia, respectively. Among all the 204 episodes of MRSA bacteraemia, a total of 21 episodes of MRSA bacteraemia (cases) (10.3%) were recorded to occur during ICU stay or immediately before ICU admission. Sixty episodes of MSSA bacteraemia (controls) (12.5%) were recorded to occur in the ICU or immediately before ICU admission among a random sample of 482 episodes of MSSA bacteraemia during the study period. The 482 episodes of MSSA bacteraemia were selected through a random number table and they were not matched with the cases. The ratio of cases to controls was about 1:3 in this study. The ICU data were retrieved from the ICU database and merged with the microbiology data to capture all essential data for each patient. Long-term survival status and causes of death were retrieved from the Death Registry of Western Australia.
The risk factors for MRSA infection considered in this study included age, Aboriginal ethnicity, immunosuppressive therapy, solid organ malignancy, haematological malignancy, end-stage renal failure requiring dialysis, diabetes mellitus, human immunodeficiency virus, intravenous drug use, hospitalisation within six months prior to the onset of bacteraemia and residence in a long-term care facility (e.g. nursing home, hostel).
The outcomes assessed in this study included whether the initial antibiotics were effective according to their in vitro activity against the bacterium, surgery to control the infection, duration of bacteraemia with the same bacterium between serial positive blood cultures, clinical features of metastatic seeding of infection, duration of fever, requirements for mechanical ventilation, inotropes and dialysis, severity of acute illness as measured by the Acute Physiology and Chronic Health Evaluation (APACHE) II score and APACHE II predicted mortality 16 , length of ICU and hospital stay, hospital mortality and death within five years after hospital discharge.
Statistical analysis
Categorical variables and continuous variables with a skewed distribution were analysed by chisquare and Mann-Whitney test, respectively. Continuous variables with a normal distribution were analysed by t-test.
Logistic regression was used to identify factors associated with hospital mortality. The factors that were initially considered included MRSA bacteraemia (vs MSSA bacteraemia), age, APACHE II predicted mortality, polymicrobial bacteraemia, duration of bacteraemia, infective endocarditis, community or healthcare associated bacteraemia, metastatic seeding of infection, catheter-related bacteraemia, time between bacteraemia and commencement of effective antibiotics, initial therapy with antibiotics with in vitro activity against the bacterium, diabetes mellitus, renal failure, immunosuppressive therapy, haematological malignancy, solid organ malignancy and human immunodeficiency virus. Variables with a P value >0.25 were removed step by step until all variables in the model were associated with a P value <0.25. Nagelkerke R 2 was used to reflect the performance of the final model 17 .
Cox proportional hazards regression was used to model the factors associated with five-year survival after hospital discharge. only hospital survivors were included in the Cox regression analysis and the survival status of the patients who were admitted to the ICU after July 2003 was censored on 26 July 2008. The factors included in the Cox regression analysis included MRSA bacteraemia (vs MSSA bacteraemia), polymicrobial bacteraemia, metastatic seeding of infection, duration of bacteraemia and infective endocarditis, age, gender, APACHE II predicted mortality and major comorbidities 18 . Variables with a P value >0.25 were removed step by step until all variables in the model were associated with a P value <0. 25 .
RESULTS
A total of 21 MRSA bacteraemia and 60 randomly selected MSSA bacteraemia episodes were considered. There was a suggestion that hospitalisation within the preceding six months (P=0.087) and residence in a long-term care facility (P=0.065) were associated with a higher risk of MRSA bacteraemia, but no single specific characteristic or comorbidity of the patients could significantly differentiate MRSA bacteraemia from MSSA bacteraemia ( Table 1) .
MRSA bacteraemia was more often treated with ineffective empirical antibiotics (38.1% vs 0%, P=0.001), associated with a longer duration of fever (median 7 vs 2 days, P=0.009) and bacteraemia (mean 3.2 vs 0.6 days, P=0.005) and a higher incidence of metastatic seeding of the infection (52.4% vs 21.7%, P=0.012) when compared to MSSA bacteraemia. Despite these differences, the proportion of patients requiring surgery to control source of sepsis, length of hospital and ICU stay, and hospital mortality were not significantly different between MRSA and MSSA bacteraemia ( Table 2 ).
In the multivariate analysis, only age (odds ratio [OR] per year increment=1.15, 95% confidence interval [CI] 1.05 to 1.26, P=0.013) and the APACHE II predicted mortality (oR per 10% increment= 1.49, 95% CI 1.06 to 2.10, P=0.022) were significantly associated with hospital mortality. MRSA bacteraemia was not significantly associated with hospital mortality (Nagelkerke R 2 =0.518) ( Table 3 ).
In the assessment of survival after hospital discharge, only end-stage renal failure requiring dialysis (hazard ratio [HR]=40.9, 95% CI 3.92 to 426.4, P=0.002) and MRSA bacteraemia (36.4% died within five years, HR=26.0, 95% CI 1.90 to 356.7, P=0.015) were significantly associated with a higher five-year mortality ( Table 4 ) ( Figure 1 ). There was also a suggestion that diabetes mellitus may be associated with a worse five-year mortality, but this was not statistically significant. According to the records in the Death Registry of Western Australia, infections contributed to 75% of the deaths after hospital discharge for the patients who had an episode of MRSA bacteraemia.
DISCUSSIoN
This study suggests that residence in a long-term care facility and hospitalisation within six months prior to the onset of sepsis might be associated with an increased risk of MRSA bacteraemia in our ICU. No single patient characteristic could, however, be reliably used to differentiate MRSA bacteraemia from MSSA bacteraemia. MRSA bacteraemia was associated with a higher risk of ineffective antibiotic treatment initially resulting in a longer duration of bacteraemia and a higher risk of metastatic seeding of the infection. While hospital outcomes were not significantly different between MRSA and MSSA bacteraemia, MRSA bacteraemia had a much higher five-year mortality than MSSA bacteraemia.
The suggestion that MRSA bacteraemia was associated with hospitalisation within six months prior to the onset of sepsis and residence in a longterm care facility was consistent with the results of some other reports 5, 6, 19 . It is, however, difficult to differentiate MRSA bacteraemia from MSSA bacteraemia clinically as supported by our findings 1 . Use of ineffective empirical antibiotics was quite frequent in our patients who had MRSA bacteraemia, resulting in a longer duration of bacteraemia and a higher risk of metastatic seeding of the infection. Similar results were also observed in another study 4 . Despite these complications of MRSA infections, our results did not demonstrate a significant difference in hospital outcomes between MRSA and MSSA bacteraemia. There are two possible explanations. First, the sample size of this study could be too small to demonstrate the difference. Second, MSSA has been reported to have a higher fitness and a growth advantage compared to MRSA 20 , but a delay in initiating effective antimicrobial therapy could have balanced out the difference in the overall mortality effect. Studies have shown that a delay in initiating glycopeptide therapy for MRSA bacteraemia can result in increased length of hospital stay and mortality, especially when it is delayed for more than 45 hours 7,21-23 . our results coupled, with the evidence from the current literature, support the use of strategies, such as realtime polymerase chain reaction 24 , which can expedite diagnosis and treatment of MRSA bacteraemia. Until the accuracy of real-time polymerase chain reaction is well established and the test is also widely available, it may be prudent to initiate early empirical glycopeptide therapy while waiting for blood culture results in patients with sepsis in ICUs where MRSA is endemic or prevalent 7, 22, 23, 25 . Semisynthetic penicillins should then be used if MSSA is isolated instead of MRSA, because these antibiotics may be more effective than glycopeptide therapy for deep-seated Staphylococcus aureus infections 14, 26 .
To the best of our knowledge, the association between MRSA bacteraemia and a higher longterm mortality after hospital discharge compared to MSSA bacteraemia has not been reported. The possible explanations may include residual confounding effect of comorbidities in patients who are prone to MRSA infections and recurrent systemic MRSA infections [13] [14] [15] 18, 27 . Because MRSA infection tends to occur in patients who have had prior hospitalisation, residence in a long-term care facility, or with significant comorbidities [4] [5] [6] [7] [8] , it is possible that the increased five-year mortality of MRSA bacteraemia was caused by residual confounding. The risk factors associated with the occurrence of MRSA bacteraemia in the first place may increase the risk of long-term mortality directly (e.g. renal failure) or through an increased risk of recurrent infections (e.g. diabetes mellitus, indwelling urinary catheter).
It is also possible that patients who experience an episode of MRSA bacteraemia may be colonised with MRSA for a prolonged period of time. Evidence suggests that MRSA colonisation can last for many years and persistent colonisation can increase the risk of recurrent MRSA infections 13, 14 . The records of those MRSA patients who died after hospital discharge showed that infections contributed to the 75% of the deaths and recurrent MRSA infections may have accounted for some of these infections. A recent study also showed that one-year survival after MRSA infections was significantly lower than MSSA infections (49% vs 68%, respectively) 28 . If our results can be further confirmed by other studies, it will be important to follow up patients with MRSA bacteraemia closely after their hospital discharge. Whether aggressive attempts to eradicate MRSA colonisation will improve their long-term outcome remains uncertain but this merits further investigation 10, 29, 30 .
This study has significant limitations. First, the incidence of MRSA bacteraemia in our ICU was low. only about 15% of all episodes of Staphylococcus aureus bacteraemia in our ICU in the past 10 years were due to MRSA, a rate lower than data from the other states of Australia 31 . This limits the power of our study. As such, our results were imprecise and may not be generalisable. Second, this was a retrospective study. Although we tried to control for most known confounders, significant confounding effect by unmeasured confounders is still possible. Finally, we used the Death Registry to identify the cause of deaths of our patients after their hospital discharge. These records have no microbiological information on the organisms that contributed to the infection and death of the patients. Whether these infections were caused by recurrent MRSA infections or other organisms remains uncertain.
In summary, no single patient characteristic could be reliably used to differentiate MRSA bacteraemia from MSSA bacteraemia in our ICU. MRSA bacteraemia was often treated with ineffective empirical antibiotics, resulting in a longer duration of bacteraemia and a higher risk of metastatic seeding of the infection. Hospital outcomes were similar between MRSA and MSSA bacteraemia but the five-year mortality after an episode of MRSA bacteraemia was much worse than MSSA bacteraemia. A prospective multicentre study with prolonged follow-up of patients with MRSA and MSSA bacteraemia is needed to confirm the long-term significance of MRSA bacteraemia.
